CB2 Pharma Information

Pre-clinical stage company targeting neuropathy and other neurodegenerative diseases. The Chief Science Officer of CB2 Pharma invented this technology while at M. D. Anderson Cancer Center and now works at Cleveland Clinic. Initial target indication prevention of chemotherapy-induced neuropathy.Chemotherapy-induced neuropathy is the 2nd largest dose-limiting toxicity of chemotherapy after hematologic toxicities, which can be treated with red or white blood cell growth factors. To date, neither prevention nor treatment strategies for chemotherapy-induced neuropathy have been effective. If a patient receiving chemotherapy develops neuropathy, the oncologist often reduces the dose or stops therapy, which can limit its efficacy. Please contact for detailed information.